In today's episode, Matt Horine speaks with Scott Maier, CEO of Virginia-based Blue Star NBR. Scott explains why the U.S. still imports about 99% of nitrile gloves and how pandemic shortages exposed major supply-chain risk. He outlines the capital, scale, and technical complexity required to reshore commodity glove production, and argues gloves are strategic for industries like semiconductors, pharmaceuticals, rare earths, magnets, and batteries. The discussion covers China’s expansion and vertical control of both glove output and raw materials, the need to treat PPE as national security infrastructure, and policy requirements such as tariffs, financing, and long-term buyer commitments (including proposed CMS reimbursement incentives for hospitals buying domestic PPE). Maier also describes workforce development efforts in southwest Virginia/Appalachia and Blue Star’s plans to complete a raw-material facility and begin building multiple glove plants.

Timestamps

00:00 Welcome to US Manufacturing Today + Introducing Scott Maier (Blue Star NBR)

01:21 Scott’s Path from Finance to Building Manufacturing Companies

02:34 The Wake-Up Call: America’s Medical Supply Vulnerability (Pre-Pandemic)

03:36 What Really Happened During the Pandemic Glove Shortages

04:55 What It Takes to Build Nitrile Glove Manufacturing in the U.S. (Scale & Capital)

06:12 Misconceptions: Why Glove Manufacturing Is Harder Than People Think

07:49 Beyond Healthcare: Gloves as a Strategic Input for Critical Industry

08:33 China’s Vertical Control of Gloves + Raw Materials (and Why It’s a Choke Point)

09:51 PPE as National Security Infrastructure & Economic Sovereignty

12:39 Policy Reality Check: Tariffs, Financing, and Buyer Commitments

14:13 Competing with Subsidized Imports: The ‘China Price’ and Raw-Input Advantage